Merck KGaA
XETRA:MRK

Watchlist Manager
Merck KGaA Logo
Merck KGaA
XETRA:MRK
Watchlist
Price: 141.75 EUR 2.49% Market Closed
Market Cap: 61.6B EUR
Have any thoughts about
Merck KGaA?
Write Note

Merck KGaA
Gross Profit

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Merck KGaA
Gross Profit Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Gross Profit CAGR 3Y CAGR 5Y CAGR 10Y
Merck KGaA
XETRA:MRK
Gross Profit
€12.3B
CAGR 3-Years
1%
CAGR 5-Years
4%
CAGR 10-Years
5%
ATAI Life Sciences NV
NASDAQ:ATAI
Gross Profit
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Bayer AG
XETRA:BAYN
Gross Profit
€26.7B
CAGR 3-Years
1%
CAGR 5-Years
1%
CAGR 10-Years
3%
MPH Health Care AG
XETRA:93M1
Gross Profit
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Dermapharm Holding SE
XETRA:DMP
Gross Profit
€749.3m
CAGR 3-Years
10%
CAGR 5-Years
16%
CAGR 10-Years
N/A
PharmaSGP Holding SE
XETRA:PSG
Gross Profit
€91.6m
CAGR 3-Years
17%
CAGR 5-Years
11%
CAGR 10-Years
N/A
No Stocks Found

Merck KGaA
Glance View

Market Cap
61.6B EUR
Industry
Pharmaceuticals

Merck KGaA, a global science and technology company based in Darmstadt, Germany, has carved out a distinctive niche in the life sciences, healthcare, and high-performance materials sectors. With a rich history tracing back to 1668, it stands as one of the oldest pharmaceutical and chemical companies in the world. Merck KGaA operates in three primary business segments: Healthcare, Life Science, and Performance Materials. The Healthcare division focuses on innovative prescription medicines and therapies, while the Life Science segment provides essential tools and services for research and production in the life sciences. Meanwhile, the Performance Materials branch offers state-of-the-art solutions for electronic applications and displays. This diverse portfolio positions Merck KGaA as a critical player in industries that are fundamental to advancements in health and technology. Investors should note that Merck KGaA has made strategic investments in research and development, committing approximately 15% of its annual revenue to this area, underscoring its dedication to innovation and growth. The company boasts a solid financial position, with a revenue forecast expected to rise steadily, driven by a robust pipeline of patented drugs and growing global demand for biopharmaceuticals. With a focus on sustainability and digital transformation, Merck KGaA is not only prepared to thrive in today’s competitive landscape but is also positioning itself for long-term success. By blending a legacy of scientific excellence with contemporary challenges, Merck KGaA represents an intriguing opportunity for investors seeking to navigate the dynamic health and technology markets.

MRK Intrinsic Value
157.06 EUR
Undervaluation 10%
Intrinsic Value
Price

See Also

What is Merck KGaA's Gross Profit?
Gross Profit
12.3B EUR

Based on the financial report for Sep 30, 2024, Merck KGaA's Gross Profit amounts to 12.3B EUR.

What is Merck KGaA's Gross Profit growth rate?
Gross Profit CAGR 10Y
5%

Over the last year, the Gross Profit growth was -5%. The average annual Gross Profit growth rates for Merck KGaA have been 1% over the past three years , 4% over the past five years , and 5% over the past ten years .

Back to Top